vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and XPEL, Inc. (XPEL). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $122.3M, roughly 1.4× XPEL, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 13.7%). Over the past eight quarters, XPEL, Inc.'s revenue compounded faster (16.5% CAGR vs 10.6%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

XPEL, Inc. is a global provider of high-performance surface protection solutions primarily for automotive use. Core offerings include paint protection films, window tints, and ceramic coatings, serving vehicle owners, dealerships, and professional installers across North America, Europe, and Asia Pacific.

ESPR vs XPEL — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.4× larger
ESPR
$168.4M
$122.3M
XPEL
Growing faster (revenue YoY)
ESPR
ESPR
+130.0% gap
ESPR
143.7%
13.7%
XPEL
Faster 2-yr revenue CAGR
XPEL
XPEL
Annualised
XPEL
16.5%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESPR
ESPR
XPEL
XPEL
Revenue
$168.4M
$122.3M
Net Profit
$13.4M
Gross Margin
41.9%
Operating Margin
50.6%
12.7%
Net Margin
11.0%
Revenue YoY
143.7%
13.7%
Net Profit YoY
50.7%
EPS (diluted)
$0.32
$0.48

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
XPEL
XPEL
Q4 25
$168.4M
$122.3M
Q3 25
$87.3M
$125.4M
Q2 25
$82.4M
$124.7M
Q1 25
$65.0M
$103.8M
Q4 24
$69.1M
$107.5M
Q3 24
$51.6M
$112.9M
Q2 24
$73.8M
$109.9M
Q1 24
$137.7M
$90.1M
Net Profit
ESPR
ESPR
XPEL
XPEL
Q4 25
$13.4M
Q3 25
$-31.3M
$12.9M
Q2 25
$-12.7M
$16.3M
Q1 25
$-40.5M
$8.6M
Q4 24
$8.9M
Q3 24
$-29.5M
$14.9M
Q2 24
$-61.9M
$15.0M
Q1 24
$61.0M
$6.7M
Gross Margin
ESPR
ESPR
XPEL
XPEL
Q4 25
41.9%
Q3 25
41.8%
Q2 25
42.9%
Q1 25
42.3%
Q4 24
40.6%
Q3 24
42.5%
Q2 24
43.5%
Q1 24
42.0%
Operating Margin
ESPR
ESPR
XPEL
XPEL
Q4 25
50.6%
12.7%
Q3 25
-11.4%
13.4%
Q2 25
8.6%
15.5%
Q1 25
-34.0%
10.7%
Q4 24
-6.4%
11.5%
Q3 24
-31.0%
16.3%
Q2 24
3.5%
17.5%
Q1 24
52.5%
10.2%
Net Margin
ESPR
ESPR
XPEL
XPEL
Q4 25
11.0%
Q3 25
-35.9%
10.3%
Q2 25
-15.4%
13.1%
Q1 25
-62.2%
8.3%
Q4 24
8.3%
Q3 24
-57.2%
13.2%
Q2 24
-83.9%
13.7%
Q1 24
44.3%
7.4%
EPS (diluted)
ESPR
ESPR
XPEL
XPEL
Q4 25
$0.32
$0.48
Q3 25
$-0.16
$0.47
Q2 25
$-0.06
$0.59
Q1 25
$-0.21
$0.31
Q4 24
$-0.14
$0.33
Q3 24
$-0.15
$0.54
Q2 24
$-0.33
$0.54
Q1 24
$0.34
$0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
XPEL
XPEL
Cash + ST InvestmentsLiquidity on hand
$167.9M
$50.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$-302.0M
$280.3M
Total Assets
$465.9M
$382.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
XPEL
XPEL
Q4 25
$167.9M
$50.9M
Q3 25
$92.4M
$64.5M
Q2 25
$86.1M
$49.6M
Q1 25
$114.6M
$23.5M
Q4 24
$144.8M
$22.1M
Q3 24
$144.7M
$21.0M
Q2 24
$189.3M
$15.0M
Q1 24
$226.6M
$8.6M
Stockholders' Equity
ESPR
ESPR
XPEL
XPEL
Q4 25
$-302.0M
$280.3M
Q3 25
$-451.4M
$269.3M
Q2 25
$-433.5M
$255.7M
Q1 25
$-426.2M
$235.5M
Q4 24
$-388.7M
$225.5M
Q3 24
$-370.2M
$218.7M
Q2 24
$-344.2M
$201.9M
Q1 24
$-294.3M
$186.4M
Total Assets
ESPR
ESPR
XPEL
XPEL
Q4 25
$465.9M
$382.5M
Q3 25
$364.0M
$387.7M
Q2 25
$347.1M
$318.1M
Q1 25
$324.0M
$294.8M
Q4 24
$343.8M
$285.6M
Q3 24
$314.1M
$273.0M
Q2 24
$352.3M
$261.8M
Q1 24
$373.1M
$258.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
XPEL
XPEL
Operating Cash FlowLast quarter
$45.2M
$2.7M
Free Cash FlowOCF − Capex
$1.6M
FCF MarginFCF / Revenue
1.3%
Capex IntensityCapex / Revenue
0.0%
0.9%
Cash ConversionOCF / Net Profit
0.20×
TTM Free Cash FlowTrailing 4 quarters
$62.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
XPEL
XPEL
Q4 25
$45.2M
$2.7M
Q3 25
$-4.3M
$33.2M
Q2 25
$-31.4M
$27.9M
Q1 25
$-22.6M
$3.2M
Q4 24
$-35.0M
$6.3M
Q3 24
$-35.3M
$19.6M
Q2 24
$-7.2M
$26.9M
Q1 24
$53.8M
$-5.0M
Free Cash Flow
ESPR
ESPR
XPEL
XPEL
Q4 25
$1.6M
Q3 25
$32.2M
Q2 25
$26.9M
Q1 25
$2.2M
Q4 24
$4.7M
Q3 24
$-35.5M
$18.3M
Q2 24
$-7.3M
$25.1M
Q1 24
$53.8M
$-7.0M
FCF Margin
ESPR
ESPR
XPEL
XPEL
Q4 25
1.3%
Q3 25
25.6%
Q2 25
21.6%
Q1 25
2.1%
Q4 24
4.4%
Q3 24
-68.7%
16.2%
Q2 24
-9.9%
22.8%
Q1 24
39.0%
-7.7%
Capex Intensity
ESPR
ESPR
XPEL
XPEL
Q4 25
0.0%
0.9%
Q3 25
0.0%
0.8%
Q2 25
0.0%
0.8%
Q1 25
0.0%
1.0%
Q4 24
0.0%
1.5%
Q3 24
0.3%
1.1%
Q2 24
0.1%
1.6%
Q1 24
0.1%
2.2%
Cash Conversion
ESPR
ESPR
XPEL
XPEL
Q4 25
0.20×
Q3 25
2.56×
Q2 25
1.71×
Q1 25
0.38×
Q4 24
0.71×
Q3 24
1.31×
Q2 24
1.79×
Q1 24
0.88×
-0.74×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

XPEL
XPEL

Products$90.9M74%
Service Revenue Installation Labor$23.8M19%
Service Revenue Cutbank Credits$4.1M3%
Service Revenue Software$2.2M2%

Related Comparisons